Double Blinded, Randomized, Placebo Controlled, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients
Latest Information Update: 18 Sep 2019
Price :
$35 *
At a glance
- Drugs Masilukast (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors SAMA Pharmaceuticals
- 13 Nov 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Jan 2015 Planned primary completion date changed from 1 Jan 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 14 Dec 2012 New trial record